Latest Deals

AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics for the development of targeted genetic medicines to treat eye diseases with high unmet needs. The latest partnership builds on the 2021 neurodegenerative disease collaboration. 

Under the expanded deal terms, Capsida will take charge of capsid discovery efforts for all the programmes, along with process development and early clinical manufacturing. AbbVie will lead therapeutic cargo approaches and handle the development and commercialisation activities. 

Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. The clinical development partnership will focus on the development of UCB6114 and UCB4594 investigational antibody candidates. It will combine Cancer Research UK’s oncology-focused translational research and clinical development capabilities and the antibody discovery expertise of UCB.

Dr Reddy’s Laboratories has signed a definitive agreement to buy Australian company Mayne Pharma Group’s US generic prescription product portfolio in a deal valued at approximately $105m. Under the deal, the company will buy the portfolio for around $90m in an upfront cash payment. Mayne Pharma’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 approved, non-marketed products. 

Sunshine Biopharma has signed an exclusive global licence deal with the University of Arizona for PLpro-based Covid-19 treatment. Under the deal, the company will gain exclusive global rights for all of the University of Arizona and University of Illinois Chicago’s technology that is related to PLpro protease inhibitors of the SARS-CoV-2 virus.